Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
暂无分享,去创建一个
O. Yang | C. Moser | J. Currier | T. Kelesidis | J. Stein | T. Brown | G. McComsey | H. Ribaudo | M. Dubé | T. T. T. Tran
[1] O. Yang,et al. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. , 2015, The Journal of infectious diseases.
[2] J. Currier,et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness , 2015, AIDS.
[3] O. Yang,et al. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] M. Lederman,et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. , 2014, The Journal of infectious diseases.
[5] R. Effros,et al. T cell replicative senescence in human aging. , 2013, Current pharmaceutical design.
[6] L. Kuller,et al. Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected Individuals , 2012, PloS one.
[7] R. Bosch,et al. CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. , 2012, The Journal of infectious diseases.
[8] P. Price,et al. Immunosenescent CD57+CD4+ T-cells Accumulate and Contribute to Interferon-γ Responses in HIV Patients Responding Stably to ART , 2011, Disease markers.
[9] F. Ceccherini‐Silberstein,et al. Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes. , 2011, Antiviral research.
[10] E. Rosenberg,et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. , 2011, The Journal of infectious diseases.
[11] Jeffrey N. Martin,et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. , 2011, The Journal of infectious diseases.
[12] A. Sharrett,et al. T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women , 2011, The Journal of infectious diseases.
[13] A. Rebuzzi,et al. Unusual CD4+CD28nullT Lymphocytes and Recurrence of Acute Coronary Events , 2007 .
[14] A. Rebuzzi,et al. Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events. , 2007, Journal of the American College of Cardiology.
[15] R. Effros,et al. Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. , 2002, Clinical immunology.
[16] N. Samani,et al. Telomere shortening in atherosclerosis , 2001, The Lancet.